The diagnostic performance of [18F]Florbetazine in Alzheimer’s disease: a head-to-head comparison to [11C]PiB and [18F]Florbetapir
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07233-y ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Meiqi Wu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Peking Union Medical Col…. Hauptthemen laut MEDLINE: Alzheimer Disease, Aniline Compounds, Benzothiazoles, Carbolines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding.
Themen: Demenz
Abstract (Originalsprache)
PURPOSE: This study aims to compare [18F]Florbetazine (FBZ, [18F]92) with [11C]Pittsburgh compound B (PiB) and [18F]Florbetapir (FBP) PET imaging to evaluate the diagnostic efficacy of FBZ and explore differences in topographical deposition patterns between FBZ and PiB/FBP. METHODS: Seventy-eight participants were included, with 40 in the FBZ-PiB subgroup (9 healthy controls [HCs], 9 with non-AD dementia, and 22 with AD) and 38 in the FBZ-FBP subgroup (10 HCs, 9 with non-AD dementia, 1 with mild cognitive impairment [MCI], and 18 with AD). All images were visually evaluated by two trained nuclear medicine physicians and quantitatively analyzed using global and regional standardized uptake value ratio (SUVr). RESULTS: Visual interpretation of FBZ scans achieved a diagnostic sensitivity of 100% and a specificity of 97%, with complete concordance with PiB and FBP. Positive FBZ PET scans showed higher gray matter uptake relative to white matter, closely resembling the cortical distribution of PiB but offering greater gray-to-white matter contrast compared to both PiB (1.19(0.17) vs. 1.11(0.15), P < 0.001) and FBP (1.27(0.24) vs. 0.86(0.13), P < 0.001). The global SUVr for all three radiotracers demonstrated perfect diagnostic accuracy for AD, with a cut-off range of 0.99 to 1.38 for FBZ when using the whole cerebellum as a reference. The global SUVr of FBZ strongly correlated with PiB (slope = 0.94, r = 0.99, P < 0.001) and FBP (slope = 1.74, r = 0.95, P < 0.001). CONCLUSION: FBZ PET imaging exhibits comparable diagnostic efficacy to PiB and FBP, with excellent correlation for Aβ quantification. Its high cortical uptake and low white matter binding favors visual interpretation in clinical practice. CLINICAL TRIAL REGISTRATION: NCT06141356. Registered November 2023. https://clinicaltrials.gov/search?term=NCT06141356 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Med…
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, China.
- Department of Neurology, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Central Research Institute, United Imaging Healthcare, Shanghai, China.
- Beijing United Imaging Research Institute of Intelligent Imaging, Beijing, China.
- Institute of Clinical Medicine, Chinese Academy of Medical Sciences, Beijing, China.
ORCID-Profile: Li Huo
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
- Shanghai Medical Innovation & Development Foundation
Zitieren
APA
Wu, M., Li, Y., Liang, M., Mao, C., Dong, L., Ge, Q., Wu, R., Ren, C., Zhang, H., Huang, Z., Xing, H., Yang, X., Wang, Y., Feng, F., Cui, M., Gao, J., & Huo, L. (2025). The diagnostic performance of [18F]Florbetazine in Alzheimer’s disease: a head-to-head comparison to [11C]PiB and [18F]Florbetapir. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07233-y
Vancouver
Wu M, Li Y, Liang M, Mao C, Dong L, Ge Q, et al. The diagnostic performance of [18F]Florbetazine in Alzheimer’s disease: a head-to-head comparison to [11C]PiB and [18F]Florbetapir. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07233-y
BibTeX
@article{Wu2025,
author = {Wu, Meiqi and Li, Yuying and Liang, Menglin and Mao, Chenhui and Dong, Liling and Ge, Qi and Wu, Runze and Ren, Chao and Zhang, Haiqiong and Huang, Zhenghai and Xing, Haiqun and Yang, Xueqian and Wang, Yuan and Feng, Feng and Cui, Mengchao and Gao, Jing and Huo, Li},
title = {The diagnostic performance of [18F]Florbetazine in Alzheimer’s disease: a head-to-head comparison to [11C]PiB and [18F]Florbetapir},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07233-y}
}
EUVIMED